1. Most Discussed
  2. Gainers & Losers
BLT 19.0¢

Panno response on Tribetarna Trial

  1. Blane66

    2,022 Posts.
    32
    Panno response about Tribetarna trial starting ....

    Author’s reply »The role of tubulin in NSCLC is still being investigated by the team. The work published late last year


    http://bit.ly/18MEYO0


    has identified tubulin's mode of action in NSCLC. This is a significant step in understanding the safety profile of Tribetarna and increases the chances of the FDA approving an IND. Assuming that the biodistribution studies are also close to completion, then the IND application should not be too far away. The only drawback that I can envisage is the biodistribution study MAY throw up some new data that needs additional work to prove the safety profile is complete. If this were to be the case, then we would need more information before the impact of any such findings could be assessed.

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.